Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension ...
Tag: pulmonology
Depemokimab therapy reduces exacerbations in patients with severe eosinophilic asthma
1. In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients with severe eosinophilic asthma. ...
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term benefits by reducing ...
Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease
1. In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was not associated with improved clinical ...
AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited-stage small cell lung cancer
1. Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. ...
Fractional dosing of pneumococcal conjugate vaccine noninferior to full dosing schedule
1. In this randomized non-inferiority trial, 40% of a full dose of the 13-valent pneumococcal conjugate vaccine (PCV13) was noninferior ...
Reduced pneumococcal vaccine schedules non-inferior to WHO recommendations
1. In this cluster-randomized controlled trial, it was found that a pneumococcal conjugate vaccine (PCV) schedule involving a single primary ...
Amivantumab plus lazertinib improves survival in EGFR-mutated advanced NSCLC
1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung ...
Adjuvant durvalumab therapy improves survival in limited-stage small cell lung cancer
1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo ...
Ziresovir reduces the severity of respiratory syncytial virus in hospitalized infants
1. Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and symptoms ...